Journal: International Journal of Molecular Sciences

Article Title: Expression of Musashi-1 During Osteogenic Differentiation of Oral MSC: An In Vitro Study

doi: 10.3390/ijms20092171

Figure Lengend Snippet: Expression of mesenchymal stromal cell (MSC) surface markers.

Article Snippet: Anti-CD90 conjugated with fluorescein-5-isothiocyanate (FITC) (eBioscence, clone eBio5E10), anti-CD73 conjugated with phycoerythrin (PE) (BD Pharmingen, cloneAD2-PE) and anti-CD105 conjugated with allophycocyanin (APC) (Serotec, clone SN6) were studied for positivity; anti-CD14-FITC (BD, clone M5E2), anti-CD31-PE (R&D, clone 9G11), anti-CD34-PE (BD, clone 2D1) and anti-CD45-APC (Caltag, clone HI30) were evaluated for negativity.

Techniques: Expressing

Journal: iScience

Article Title: NFAT signaling in human mesenchymal stromal cells affects extracellular matrix remodeling and antifungal immune responses

doi: 10.1016/j.isci.2021.102683

Figure Lengend Snippet:

Article Snippet: CD105 (Endoglin) Monoclonal Antibody (SN6), eFluor 450, eBioscience™ , Thermo Fisher Scientific , Cat# 48-1057-42, RRID: AB_11219684.

Techniques: Produced, Recombinant, Lysis, Western Blot, Bicinchoninic Acid Protein Assay, Enzyme-linked Immunosorbent Assay, RNA Sequencing Assay, Derivative Assay, Software

Journal: Stem Cell Research & Therapy

Article Title: A novel serum-free medium for the expansion of human mesenchymal stem cells

doi: 10.1186/scrt8

Figure Lengend Snippet: Flow-cytometric analysis of expanded human MSCs

Article Snippet: Passage 3 human MSCs expanded in SCM or SFM were harvested by using TrypLE™ Express and washed with DPBS (without Ca 2+ /Mg 2+ ) supplemented with 5% FBS and stained with the following antibodies: CD11b (unconjugated, clone VIM12), CD34-APC (clone 581), CD45-AF405 (clone HI30), CD44-PE (clone MEM-85), CD105-APC (clone SN6), (all from Invitrogen); CD90 (clone 5E10), CD73-PE (clone AD2), (both from BD Biosciences); and where unconjugated primary antibodies were used, AlexaFluor ® 488 anti-mouse (Invitrogen).

Techniques: Cytometry, Flow Cytometry

Journal: Stem Cell Research & Therapy

Article Title: A novel serum-free medium for the expansion of human mesenchymal stem cells

doi: 10.1186/scrt8

Figure Lengend Snippet: Quantitative real-time PCR analysis of expanded human MSCs

Article Snippet: Passage 3 human MSCs expanded in SCM or SFM were harvested by using TrypLE™ Express and washed with DPBS (without Ca 2+ /Mg 2+ ) supplemented with 5% FBS and stained with the following antibodies: CD11b (unconjugated, clone VIM12), CD34-APC (clone 581), CD45-AF405 (clone HI30), CD44-PE (clone MEM-85), CD105-APC (clone SN6), (all from Invitrogen); CD90 (clone 5E10), CD73-PE (clone AD2), (both from BD Biosciences); and where unconjugated primary antibodies were used, AlexaFluor ® 488 anti-mouse (Invitrogen).

Techniques: Real-time Polymerase Chain Reaction, Expressing

Journal: Scientific Reports

Article Title: CD105 (Endoglin) as negative prognostic factor in AML

doi: 10.1038/s41598-019-54767-x

Figure Lengend Snippet: Generation and functional characterization of CD105 antibody K-ro23. The CD105 antibody K-ro23 was generated as described in the methods section. ( A ) Size exclusion chromatography after the initial purification with protein A affinity chromatography. ( B ) SDS-PAGE analysis under reducing (R) and non-reducing conditions (NR). ( C ) Flow cytometry based detection of specific binding of the CD105 antibody (shaded peaks) and an isotype control (open peaks) at 1 nM on CD105 transfected Sp2/0 and mock transfected Sp2/0, and ( D ) analysis of the binding capacity of the CD105 antibody on CD105 transfected and mock transfected Sp2/0 as negative control. ( E ) Comparison of the specific binding of K-ro23 and the commercial clones SN6 and 166707 (shaded peaks) compared to the respective isotype controls (open peaks) at 5 nM on acute leukaemia cell lines. ( F ) Titration of the different CD105 clones on acute leukaemia cell lines. Specific fluorescence intensity (SFI) levels are shown.

Article Snippet: Unconjugated anti-CD105 mAb (clone K-ro23 and clone SN6, Santa Cruz Biotechnology, Dallas, TX) or isotype control (clone MPC-11, BD Biosciences, Heidelberg, Germany) as well as the comparative anti-CD105 clone 166707 (R&D Systems, Minneapolis, MN) and the respective isotype control (IgG1 isotype, clone MG1-45, BioLegend) were added at 5 nM, followed by a mouse-specific PE conjugate (1:100).

Techniques: Functional Assay, Generated, Size-exclusion Chromatography, Purification, Affinity Chromatography, SDS Page, Flow Cytometry, Binding Assay, Control, Transfection, Negative Control, Comparison, Clone Assay, Titration, Fluorescence

Journal: Scientific Reports

Article Title: CD105 (Endoglin) as negative prognostic factor in AML

doi: 10.1038/s41598-019-54767-x

Figure Lengend Snippet: CD105 expression on malignant haematopoietic cells. ( A ) Immunohistochemistry of CD105 expression of two exemplary AML patients. ( B ) Exemplary gating for two AML samples with the respective isotype control and specific CD105 binding. Specific gating strategy and controls are shown in Fig. S2. ( C – G ) CD105 expression was analysed on AML cells by flow cytometry. SFI levels above 1.5 were considered as positive expression (dotted line) ( C ) CD105 expression on blasts of AML patients (n = 62) are depicted as percentage of CD105 positive blasts and SFI levels (boxplots with Tukey whiskers). ( D – F ) CD105 SFI levels are depicted for the different FAB types (single values, median; Kruskal-Wallis-test) ( D ), FAB M3 vs. others FAB (boxplots with Tukey whiskers; Mann-Whitney-test) ( E ) and according to favourable and unfavourable FAB classification (boxplots with Tukey whiskers; Mann-Whitney-test) ( F ) are shown. ( G ) Distribution of CD105 expression (SFI) throughout NCCN risk group (boxplots with Tukey whiskers; Kruskal-Wallis-test).

Article Snippet: Unconjugated anti-CD105 mAb (clone K-ro23 and clone SN6, Santa Cruz Biotechnology, Dallas, TX) or isotype control (clone MPC-11, BD Biosciences, Heidelberg, Germany) as well as the comparative anti-CD105 clone 166707 (R&D Systems, Minneapolis, MN) and the respective isotype control (IgG1 isotype, clone MG1-45, BioLegend) were added at 5 nM, followed by a mouse-specific PE conjugate (1:100).

Techniques: Expressing, Immunohistochemistry, Control, Binding Assay, Flow Cytometry, MANN-WHITNEY

Journal: Scientific Reports

Article Title: CD105 (Endoglin) as negative prognostic factor in AML

doi: 10.1038/s41598-019-54767-x

Figure Lengend Snippet: Impact of CD105 expression on clinical outcome. ( A ) Specific binding of the CD105 antibody (shaded peaks) and an isotype control (open peaks) at 5 nM on AML blasts from exemplary patients of quartiles 1–4 using flow cytometry. ( B ) Kaplan-Meier analysis of SFI levels of CD105. Overall survival (OS) of each SFI quartile (1 st : 1–2.42; 2 nd : 2.43–5.25; 3 rd :5.26–26.37; 4 th : 26.38–65.2) was plotted followed by statistical analysis with log-rank test. ( C ) ROC for SFI levels of CD105 and OS were plotted. The crossing of the dotted line and the ROC curve marks the Youden-index for the highest sensitivity and specificity. ( D ) Overall survival according to CD105 lo and CD105 hi expression in Kaplan-Meier analysis. Mean OS was reached in CD105 hi after 199 days (dotted line; log-rank test). ( E ) PFS after any AML specific treatment according to CD105 lo and CD105 hi expression in Kaplan-Meier analysis. In CD105 hi the mean PFS was 383 days (dotted line; log-rank test).

Article Snippet: Unconjugated anti-CD105 mAb (clone K-ro23 and clone SN6, Santa Cruz Biotechnology, Dallas, TX) or isotype control (clone MPC-11, BD Biosciences, Heidelberg, Germany) as well as the comparative anti-CD105 clone 166707 (R&D Systems, Minneapolis, MN) and the respective isotype control (IgG1 isotype, clone MG1-45, BioLegend) were added at 5 nM, followed by a mouse-specific PE conjugate (1:100).

Techniques: Expressing, Binding Assay, Control, Flow Cytometry

Journal: Scientific Reports

Article Title: CD105 (Endoglin) as negative prognostic factor in AML

doi: 10.1038/s41598-019-54767-x

Figure Lengend Snippet: Distribution of patient characteristics according to CD105 quartiles.

Article Snippet: Unconjugated anti-CD105 mAb (clone K-ro23 and clone SN6, Santa Cruz Biotechnology, Dallas, TX) or isotype control (clone MPC-11, BD Biosciences, Heidelberg, Germany) as well as the comparative anti-CD105 clone 166707 (R&D Systems, Minneapolis, MN) and the respective isotype control (IgG1 isotype, clone MG1-45, BioLegend) were added at 5 nM, followed by a mouse-specific PE conjugate (1:100).

Techniques:

Journal: Scientific Reports

Article Title: CD105 (Endoglin) as negative prognostic factor in AML

doi: 10.1038/s41598-019-54767-x

Figure Lengend Snippet: Distribution of patient characteristics according to CD105 lo and CD105 hi .

Article Snippet: Unconjugated anti-CD105 mAb (clone K-ro23 and clone SN6, Santa Cruz Biotechnology, Dallas, TX) or isotype control (clone MPC-11, BD Biosciences, Heidelberg, Germany) as well as the comparative anti-CD105 clone 166707 (R&D Systems, Minneapolis, MN) and the respective isotype control (IgG1 isotype, clone MG1-45, BioLegend) were added at 5 nM, followed by a mouse-specific PE conjugate (1:100).

Techniques: